MAP3K21 and cancer: Because specific pharmacological inhibitors for MLK4 are lacking, we had to select the first generation MLK inhibitor K252a and the newer class of more selective MLK inhibitor URMC-099 to examine the effect of these inhibitors on cancer cells.